Lori Jean van Orden

Lori Jean Van Orden has a strong background in preclinical sciences, with experience in various leadership roles. Lori Jean started their career at Theravance Biopharma, Inc. as a Scientist, where they designed and synthesized compounds for non-disclosed targets. Lori Jean later became a Research Scientist and played a key role in the discovery of TD-9855, a Phase III clinical asset for orthostatic hypotension. In 2015, they joined BlackThorn Therapeutics as an Associate Director of Preclinical Sciences, leading discovery programs for neurodevelopmental diseases. Lori Jean quickly progressed to become the Director of Preclinical Sciences, where they led the Kappa Opioid Receptor Antagonist Program and facilitated the submission of an IND. In 2019, they were promoted to Senior Director of Preclinical Sciences, taking on additional responsibilities for clinical programs. Most recently, Lori Jean Van Orden became the VP of Preclinical Sciences at Neumora through an acquisition, overseeing safety, toxicology, DMPK, and clinical pharmacology for the company's portfolio.

Lori Jean Van Orden holds a PhD in Organic Chemistry from UC Irvine and a BS in Chemistry/Biochemistry from the University of North Carolina at Chapel Hill.